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Due to the low structural diversity within the set of antimalarial drugs currently available in
the clinic and the increasing number of cases of resistance, there is an urgent need to find
new compounds with novel modes of action to treat the disease. Microbial natural products
are characterized by their large diversity provided in terms of the chemical complexity of the
compounds and the novelty of structures. Microbial natural products extracts have been
underexplored in the search for new antiparasitic drugs and even more so in the discovery
of new antimalarials. Our objective was to find new druggable natural products with antima-
larial properties from the MEDINA natural products collection, one of the largest natural
product libraries harboring more than 130,000 microbial extracts. In this work, we describe
the optimization process and the results of a phenotypic high throughput screen (HTS)
based on measurements of Plasmodium lactate dehydrogenase. A subset of more than
20,000 extracts from the MEDINA microbial products collection has been explored, leading
to the discovery of 3 new compounds with antimalarial activity. In addition, we report on the
novel antiplasmodial activity of 4 previously described natural products.
Introduction
Malaria is widespread in tropical and subtropical regions, including parts of America, Asia and
Africa. An estimated 3.2 billion people are at the risk of suffering malaria and from one-half to
one million deaths were reported in 2014 (World Malaria Report. 2014). In 2014, 97 countries
and territories had ongoing malaria transmission. Most deaths from malaria are caused by
Plasmodium falciparum, one of the five species of human infectious malaria parasites. The
increasing resistance of P. falciparum to the available drugs [1] and new efforts to eradicate
malaria all drive the need to develop new, effective and affordable antimalarial agents.
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Despite the development of new technologies to study resistance acquisition [2–4] and our
increasing understanding of P. falciparum biology, few new drug targets have been clinically
validated. At present, there are only four classes of valid antimalarial compounds: quinine or
other aminoquinolines, antifolate compounds, artemisinin derivatives, and the hydroxyl
napthoquinone atovaquone. This lack of structural diversity denotes a need to explore other
sources of structures, and natural products from microorganisms render a unique chemical
space for this purpose.
Natural products are one of the most important sources for new chemical scaffolds. They
have been largely exploited in the discovery of new drugs, and around 60% of the drugs avail-
able nowadays derive directly or indirectly from natural products [5, 6]. Many of the antibi-
otics or drugs in use such as camptothecin, lovastatin, maytansine, paclitaxel, reserpine and
silibinin are all natural products. Some of the first-line malaria treatments currently used are
isolated from plants, such as artemisin and quinine. On the other hand, microbial natural
products have been underexplored in this field, although they offer great advantages for the
potential discovery of novel bioactive products and the possibility of large-scale production.
Unfortunately, to date, natural product libraries have not been extensively used in the
search for new antimalarials in large-scale campaigns using high throughput screening
(HTS) [7, 8].
Drug discovery through HTS allows the large-scale testing of potentially active products,
accelerating the identification of molecules for further development. There are several meth-
ods for detecting erythrocyte infection and drug susceptibility. However, not all of these assay
formats are suitable for HTS due to several factors such as cost, safety, assay stability, equip-
ment availability and quality of data produced. Frequently, methods for HTS technology are
based on the measurement of DNA content in strains of malaria parasites using SYBR Green
[9], GFP [10], and 4',6'-diamidino-2-phenylindole [11], or in a stably expressed cytoplasmic
firefly luciferase parasite strain (3D7-luc) [12, 13]. Nevertheless, since its description [14], the
lactate dehydrogenase (LDH) assay has been increasingly used for Plasmodium growth deter-
mination, due to its robustness and specificity. PfLDH activity measurements, which are pro-
portional to culture parasitaemia, provide specificity through the use of 3-acetylpyridine
adenine dinucleotide (APAD) as cofactor, since the human homologue present in red blood
cells carries out this reaction at a very slow rate in the presence of this cofactor instead of
NADH. In the present work, we have screened more than 20,000 natural extracts from the
MEDINA collection against P. falciparum using the assay based on LDH activity. This is the
first time that this screening approach has been applied directly to the study of natural extracts
from a high diversity of microorganisms. Using this methodology, we have identified 7 com-
pounds with antimalarial activity. Three are new/novel structures of which two have been pre-
viously described as a result of this screening [15, 16] while pepstatin K is reported herein for
the first time. Four are known compounds whose antimalarial properties had not been previ-
ously reported. All these findings provide an encouraging starting point that supports a reno-
vated interest in discovering and optimizing novel antimalarial compounds from microbial
natural products.
Materials and Methods
No specific permissions were required for the collection of samples in the Vallibierca valley,
Huesca, Spain because Spanish legislation does not regulate the access to soils in public
areas (since it is neither a National Park nor a private owned land). We confirm that the
studies involve only soil samples and these samples do not involve endangered or protected
species.
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Reagents
AlbuMAX II, RPMI medium 1640 and SYBR Green I nucleic acid gel stain were purchased
from Gibco (Life Technologies, Carlsbad, CA, USA). Gentamicin, hypoxanthine, chloroquine
diphosphate salt, sodium l-lactate, APAD, nitrotrezalium blue chloride (NBT) and diaphorase
from Clostridium kluyveri were obtained from Sigma Aldrich (St. Louis, MO, USA).
Cultivation of P. falciparum
Cultures of P. falciparum strain 3D7 were maintained in fresh type 0 positive (0+) human
erythrocytes (Centro Regional de Transfusiones Sanguíneas-Biobanco, Granada) suspended at
5% hematocrit in complete medium containing 2% human 0+ serum, 0.5% albuMAX II
(Gibco), 12.5 μg/mL gentamicin (Sigma Aldrich), 0.2% sodium bicarbonate (Sigma), 150 μM
hypoxanthine (Sigma Aldrich), and 10.4 g/L RPMI 1640 (Gibco) pH 7.2. Cultures were incu-
bated at 37°C under a gas mixture of 5% CO2, 1% O2 and 94% N2. For general cultures, para-
sites were maintained in non-synchronous forms between 0.1% and 8% parasitaemia in 75 mm
flasks. Parasite growth was monitored using thin blood smears fixed in 100% methanol and
stained for 20–30 min in 10% Giemsa solution.
Preparation of P. falciparum cultures for assay
The parasite P. falciparum 3D7 cultures were synchronized using 5% sorbitol as previously
described [17] and 96 h later, the level of parasitaemia was determined by light microscopy
counting of a minimum of 500 erythrocytes on a Giemsa-stained thin blood smear. Parasites
were noted to be late-ring and early trophozoites. The stock culture was then diluted with com-
plete medium and normal human erythrocytes to a starting 2% hematocrit and 0.25% parasi-
taemia in 25 μL of volume for 384-well plates (LDH assay) and 5% hematocrit and 0.5%
parasitaemia in 90 μL for 96-well plates (fluorescent assay). Both were incubated at 37°C for 72
h and then frozen for at least 24 h.
LDH assay conditions
The extracts, fractions and pure compounds were evaluated in 384-well plates after 72 h of
incubation. Each plate also included positive growth controls, where only medium was added,
and negative growth controls with 100 nM of chloroquine. Plates were thawed at room temper-
ature for at least 1 h. To evaluate LDH activity, 70 μL of freshly made reaction mix, containing
143 mM sodium l-lactate, 143 μMAPAD, 178.75 μMNBT, 1 U/mL diaphorase, 0.7% Tween
20 and 100 mM Tris-HCl (pH 8.0) were dispensed into plates. Plates were shaken to ensure
mixing and absorbance was measured at 650 nm after 10 min of incubation at room tempera-
ture. Absorbance was determined with a microplate reader VICTOR2Wallac spectrofluorome-
ter. The read time for each plate was 3 minutes. Plates were prepared at 3.5 minute intervals
and read in a sequential order in the plate reader. This method gives a signal to noise ratio of
10 under the conditions used [18]. With the 384-well plates, integrity of erythrocytes and LDH
activity can be inspected visually, allowing for the rapid detection of dispensing errors and
interferences by extracts. Yellow wells contain active inhibitors where parasite growth has been
abolished and the LDH reaction has been inhibited. The EC50 for chloroquine obtained this
way was 8.72 ± 0.29 nM (S1 Fig), which was similar to previously reported values [19–21].
SYBRGreen assay conditions
For the fluorescence assay, after 72 h of growth, 100 μL of SYBR Green I in lysis buffer (0.2 μL
of SYBR Green I/mL of lysis buffer containing 20 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.008%
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saponin and 0.08% Triton X-100) was added to each well, and the contents were mixed. After 2
h of incubation in the dark at room temperature, fluorescence was measured with a Spectra
MAX GEMINI EMmicroplate reader (Molecular Devices) with excitation and emission wave-
lengths of 485 and 530 nm, respectively.
Absorbance measurement, visual inspection and statistical analyses
The inhibition percentage of each extract was determined by the equation:




Where Aneg is the optical density of the negative control at 650 nm and Apos is the optical den-
sity of the positive control at 650 nm. Data were analyzed using the Genedata Screener pro-
gram, Condoseo module (Genedata AG, Switzerland). An extract was considered to have
activity when the percentage of growth inhibition was higher than 70%. The Z’ factor predicts
the robustness of an assay by taking into account the mean and standard deviation of both pos-
itive and negative assay controls. The robust Z’ factor (RZ’ factor) is based on the Z’ factor, but
standard deviations and means are replaced by the robust standard deviations and medians,
respectively. In all experiments performed in this work where a minimum of 700 384-well
plates have been used, the RZ’ factor obtained was between 0.7–0.8.
Microbial extracts collection
For the primary screening campaign, a subset of 20,000 microbial extracts from different mod-
ules of the MEDINA natural products collection (Table 1) was used. The microbial extracts
were obtained from bacterial and fungal strains cultivated in different nutritional conditions
and extracted with acetone (1:1) for 1 h in an orbital shaker. Extracts were then centrifuged at
1500 xg for 15 min and the supernatant concentrated to half the volume in the presence or not
of a final concentration of 20% DMSO. Extracts were stored at -20°C in 96-well ABgene v-bot-
tom plates until needed.
Primary screening and dose-response experiments
All the extracts were first screened against P. falciparum and those exhibiting over 70% growth
inhibition were selected as actives and confirmed in the LDH and SYRB Green assays. The
extracts selected from this stage were then tested in a five-point dose-response assay, using as
the first titration point the dilution identified as active in the primary screen and then perform-
ing four subsequent 2-fold serial dilutions. Extracts that exhibited dose-responses indicative of
good potency were selected for de-replication by tandem liquid chromatography mass spec-
trometry (LC-MS). LC-MS analyses were carried out as described previously [22].
Table 1. Characteristics of the collections assayed against P. falciparum.
Organism Solvent Other characteristics
Module A Fungi and bacteria
(actinomycetes)
100% water, 1x whole broth equivalent
(WBE)
Wide microbial diversity and production conditions
Module B Fungi and bacteria
(actinomycetes)
20% DMSO/water, 1x WBE Enriched module containing selected strains producing bioactive
compounds
Module C Non-ﬁlamenting bacteria 20% DMSO/water 4x WBE Diverse bacterial taxa
doi:10.1371/journal.pone.0145812.t001
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Bioassay-guided extract fractionation
Extracts with LC-MS profiles suggestive of containing active novel compounds were selected to
confirm the activity from a 100 mL regrowth of the producing strain in the same production
conditions [22, 23]. Hits containing compounds of interest detected in the previous step were
regrowth at 1 L scale. Extraction with acetone and a first chromatographic separation using SP-
207ss brominated polystyrenic resin was performed as previously described [16]. Active frac-
tions from this first chromatographic step were subjected to one or several steps of preparative
and semi-preparative reversed phase HPLC on a Gilson GX-281 apparatus until a pure com-
pound was obtained. The chromatographic column, solvent system and gradient conditions
for each HPLC separation were selected depending on the particular compound of interest
contained in each sample.
Isolation of pepstatins A and K
The compounds were isolated from 1 L growth of Kitasatospora mediocidica F-136,264. The
producing strain was isolated from a soil sample collected under a Juniperus communis tree col-
lected in the Vallibierca valley, Huesca, Spain. A seed culture of strain F-136,264 was prepared
in a inoculum medium (soluble starch 20 g/L, dextrose 10 g/L, NZ amine EKC (Sigma) 5 g/L,
Difco beef extract 3 g/L, Bacto peptone 5 g/L, yeast extract 5 g/L, and CaCO3 1 g/L, adjusted to
pH 7.0 with NaOH before addition of 1g/L CaCO3), at 28°C with 220 rpm orbital shaking. A
5% (v/v) of the seed culture was used to inoculate each of the seven 500 mL flasks containing
150 mL of the production medium (corn dextrin 20 g/L, beta cyclo dextrin 10 g/L, tomato
paste 20 g/L, Bacto yeast extract 10 g/L, CoCl2.6H2O 5 mg/L), and the flasks were incubated at
28°C for 7 days in a rotary shaker at 220 rpm and 70% humidity before harvesting. The 1 L cul-
ture was extracted with acetone (1 L) under continuous shaking at 220 rpm for 3 h. The myce-
lium was then separated by centrifugation and the supernatant (ca. 2 L) was concentrated to 1
L under a stream of nitrogen. This solution was loaded (with continuous 1:1 water dilution, dis-
carding the flow-through) on a column packed with SP-207SS reversed phase resin (bromi-
nated styrenic polymer, 65 g) previously equilibrated with water. The column was further
washed with water (1 L) and afterwards eluted at 8 mL/min on an automatic flash-chromatog-
raphy system (CombiFlashRf, Teledyne Isco) using a linear gradient from 10% to 100% acetone
in water (in 12.5 min) with a final 100% acetone step of 15 min, collecting 9 fractions of 20 mL.
LC-MS analysis allowed the identification of pepstatin A [24] and a new member of this family
of compounds that we designated as pepstatin K in the bioactive fraction. This fraction was fur-
ther purified by reversed phase semipreparative HPLC (Agilent Zorbax SB-C8, 9.4 × 250 mm,
7 um; 3.6 mL/min, UV detection at 210 nm) with a linear gradient of water-CH3CN of 5% to
100% CH3CN over 37 min to yield pure pepstatin A (11 mg) and pepstatin K (8 mg).
Results
Optimization of assay in a 384-well format
For the primary screening of a subset of the MEDINA collection, the PfLDH assay was used.
This methodology has been previously reported to be adequate for a 384-well plate format in
HTS [18], being a robust, sensitive, selective and reproducible assay. We adapted the method
to our laboratory conditions and facilities. Firstly, we tried different hematocrits and parasitae-
mias including those described in the above-mentioned paper. However, while conditions such
as 5% haematocrit and 0.5% parasitaemia gave rise to limited linearity of the assay, a 2% hae-
matocrit and 0.25% parasitaemia provided a perfect correlation between growth and signal. In
addition, we tested different concentrations of diaphorase ranging from 2.83 U/mL to 0.5 U/
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mL, not observing differences in the slope of the curve. On the other hand, concentrations
below 0.5 U/mL gave lower rates (Fig 1A) and, thus, the final concentration of diaphorase to be
used in the screening was established at 1 U/mL.
The SYBR Green protocol was used as a confirmatory counter-assay in a 96-well plate for-
mat [25]. This assay quantifies DNA (number of parasites) and thus allows to disregard
extracts that interfere or are inhibitors in the LDH assay. Other fluorescent DNA dyes such as
YOYO and the mixture of YOYO and SYBR Green, a combination previously used in HTS
campaigns [26], were also tested (data not shown).
Fig 1. Screening set up. A. Different diaphorase concentrations in the developing buffer were assayed. The
absorbance was measured kinetically, taking absorbance data every two minutes verifying that the linearity
of the assay comprises the 10 first minutes, time used for the development of plates. B. Percentage of hit
rates depending on the dilution applied and the organism origin of the extract. Different dilutions were applied
in a pilot sample of module A, comprising both actinomycetes and fungi. Extracts with 70% parasite growth
inhibition were selected as hits.
doi:10.1371/journal.pone.0145812.g001
Microbial Natural Products as Antimalarials
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MEDINA’s extract collection comprises various modules, characterized by the diversity of
the microbial strains represented (mainly bacteria, actinomycetes and fungi), the complexity of
the natural product extracts (whole broth crude extracts, SPE extracts or fractions) and the dif-
ferent extraction procedures. We defined the sample dilutions to be applied to the different
modules of the collection in the assay according to the percentage of positive hits obtained, to
achieve a representative number of hits that could be adequately handled in terms of scale up
capabilities. In order to adjust the most appropriate assay dilution of the original collection, we
tested crude extracts from actinomycetes and from fungi at three different concentrations. The
desired hit rate per 384-well plate was approximately 2.5% when applying a cut-off value for
positives of 70% growth inhibition. In both cases, the hit rate decreased with increasing dilu-
tions. Extracts from actinomycetes showed a higher hit rate than extracts from fungi and con-
sequently the dilutions set for these extracts were 1/200 and 1/50, respectively (Fig 1B).
Certain modules of the MEDINA extract collection contain 20% of DMSO, a solvent that
inhibits Plasmodium growth at concentrations as low as 0.001%. To avoid side effects due to
DMSO, aliquots of these extracts were previously evaporated, thus eliminating all the DMSO
present, and re-dissolved in methanol, a solvent which is less aggressive against Plasmodium
cultures and does not affect parasite growth even at 1%.
Screening campaigns, identification of actives and LC-MS de-replication
The MEDINA microbial natural product collection is composed of different modules. Ini-
tially, we focused our studies on a subset of 11,124 extracts from module A, containing both
fungi and actinomycetes extracts in aqueous solution. A second subset of 8,560 extracts was
selected from module B, containing fungal and bacterial extracts from previously selected
strains known to produce antimicrobial activities. Extracts from this module contained 20%
DMSO, and required a total evaporation followed by re-dissolving in methanol prior to the
assay. Lastly, a third subset was selected from module C containing 560 extracts from bacteria
of the classes Proteobacteria and Bacteroidetes in 20% DMSO. Since the assay dilution applied
in this latter case was significantly high (1/3000), elimination of DMSO was not necessary
(Table 1). Potential hits obtained in the primary screening were tested again in triplicate. We
established that 70% of the hits obtained in the primary screen were confirmed to be active
when assayed again in triplicate in an independent assay. The confirmed hits were then sub-
jected to dose-response curves of at least 8 points obtained from serial dilutions of the extracts
and using the PfLDH assay to establish potency. Extracts with a capacity to inhibit growth of
at least 70% when diluted 8 times were then assayed in dose-response experiments with the
secondary SYBR Green assay (Fig 2). While interference in fluorescent intensity assays in gen-
eral by natural product extracts is well documented [27, 28], here the SYBR Green assay is
used as a counter screen and it is unlikely that extract interference is an issue in both absor-
bance and fluorescence based assays. Therefore, all the extracts corroborating the inhibition
in this assay were considered as confirmed positive hits of the primary screening. As new anti-
malarial compounds were sought, and in order to avoid the growth of extracts with known
toxic compounds, all the confirmed hits obtained in the primary screening were subjected to
LC-MS analysis, which allows the detection and identification of the main components of the
extract.
The known compounds detected by LC-MS are shown in Fig 3. A database search was per-
formed using an in-house developed application, which matches UV-LC-MS data of metabo-
lites in the active extracts to UV-LC-MS data of known metabolites stored in our proprietary
database obtained using the same LC-MS conditions [23]. The results are presented taking into
account the source of the extract, actinomycetes or fungi. In the case of actinomycetes,
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antibiotics such as nigericins, oligomycins and actinomycins, among others, were identified.
Nigericins are ionophores that catalyze the electroneutral exchange of K+ for H+ [29], whereas
oligomycins and actinomycins act at the level of mitochondrial function and transcription,
respectively [30, 31]. Many of the known compounds identified are produced by species of the
genus Streptomyces. A total of 11% (actinomycetes) and 25% (fungi) of the hits correspond to
known compounds that were detected at low frequency in the positive extracts. In the case of
fungi, several known compounds such as the leucinostatins were identified, which have been
shown to exert their cytotoxic action by perturbing mitochondrial oxidative phosphorylation
[32]. Up to 45% of the hits correspond to extracts in which no known compounds were identi-
fied using MEDINA’s proprietary database.
After de-replication of extracts with known compounds, 60 extracts of module A, 150 of
module B and 21 of module C were chosen for further characterization. Nineteen extracts from
actinomycetes and 28 from fungi from module B were chosen for further scale-up according to
the potency and the taxonomy of the producing strains. In the case of module C, since the data
of cytotoxicity in three different human cell lines were available, only those extracts with no
previously described cytotoxic effect were subjected to small scale growth, thereby reducing the
number of extracts from 21 to 5.
Small scale growth for bioassay-guided fractionation
After primary screening and hit selection, a critical step was the reproduction of the activity
observed against P. falciparum in a new growth of the microorganism, assuring that the com-
pound responsible for growth inhibition is present in the new extract. This confirmation was
carried out in two phases, first a small scale growth (100 mL volume) was performed and, after
confirmation of the bioactivity, a second large scale growth (1 L) was carried out to generate
enough material for the isolation of the active molecule.
After small scale growth, the extracts generated were assayed in dose-response experiments
to confirm inhibition of Plasmodium growth of more than 70%. Once the activity was con-
firmed, the positive samples were subjected to semipreparative HPLC fractionation, and the
resulting fractions (80 fractions per sample) were analyzed for antiplasmodial activity. Plates
were assayed at different concentrations to delimit the fractions containing the highest percent-
age of growth inhibition and, thus, identifying those that contain higher amounts of the most
Fig 2. Examples of confirmation of the hits obtained in the primary assay. Both the LDH and SYBRGreen assays were used for the confirmation of the
positive extracts of the primary screening.
doi:10.1371/journal.pone.0145812.g002
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Fig 3. Compounds detected by LC-MS among the positive extracts of module A. The known products
detected are presented depending on the microorganism origin of the extract (fungi or actinomycetes). The
group of underrepresented compounds comprises all the compounds that are detected in only one extract.
doi:10.1371/journal.pone.0145812.g003
Microbial Natural Products as Antimalarials
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potent bioactive components. Once defined, the presence of known compounds was again
established by LC-MS and LC-HRMS. After growth and fraction analysis, 17 extracts were fur-
ther confirmed as containing potentially novel compounds and therefore selected for scale-up
growth and isolation of the bioactive components.
Growth scale-up and bioassay-guided purification
After verification of the antimalarial compound production in the small scale growth, the pro-
ducing strain was cultivated in higher volumes (1 L), in order to provide enough sample for
purifying the compounds responsible for the antimalarial activity. After this growth step, the
extracts produced were first subjected to a low-resolution chromatographic step on SP-207ss
resin generating 8–10 fractions, each of which was evaluated in a dose-response manner
against P. falciparum. The most active fractions were then separated into several fractions by
semipreparative or preparative HPLC, in a similar way to the procedure followed for the small
scale regrowth. Fractions and subfractions were assayed for antiplasmodial activity and pure
compounds responsible for the activity were re-purified from the most active fractions through
semipreparative HPLC.
Identification of pure compounds
Although not initially identified, final purification allowed for the identification of four known
bioactive fungal compounds: aselacin A, petasol, sporidesmin A and conglobatin. In addition,
three new compounds were identified. One is pepstatin K, a new peptide belonging to the pep-
statin family containing two units of the unusual γ-amino acid statin ((3S,4S)-4-amino-3-
hydroxy-6-methylheptanoic acid) produced by the Kitasatopora mediocidica F-136,264. On
the other hand lasionectrin produced by Lasionectria sp. CF-176994, a naphtopyrone first dis-
covered in this screening and which has been recently purified from fungal extracts [15] and a
novel fungal betaine lipid MDN-0104 produced by Heterospora chenopolii CBS109836 were
obtained [16]. We have previously reported the isolation and structures of these two latter
compounds [15, 16]. Additionally two new cyclic peptides and a new tetramic acid are pres-
ently under evaluation and will be published elsewhere. The structure and EC50 obtained for
each compound is indicated in Fig 4.
Structural characterization of pepstatin K
A pseudomolecular ion at m/z 720.4555 obtained by ESI-TOF analysis established a molecular
formula of C37H61N5O9 for pepstatin K (calc. for C37H62N5O9
+ 720.4542). Analysis of the 1D
(1H and 13C) and 2D (COSY, HSQC and HMBC) NMR spectra of the compound (Table 2)
revealed the presence in the molecule of several amino acid units, including two valine, one ala-
nine and two statine residues. Additionally, several signals in the low field region of the 1H
NMR spectrum and the presence of six signals in the sp2 region of the 13C NMR spectrum
accounted for the presence in the molecule of a phenyl containing residue that was eventually
identified as 2-phenyletanoic acid (PE) based on correlations observed in the HMBC spectrum.
The sequence of amino acid residues was partially established by analysis of key cross-peaks
observed in the HMBC spectrum and MS/MS fragmentation (Fig 5). Thus, a correlation
between the proton at δH 4.31 and a carbon at δC 173.8 was indicative of the partial sequence
Sta 2-Ala. Additional correlations between proton signals at δH 4.10 and 4.18 to carbons at δC
173.9 and 174.2, respectively, confirmed the sequence PE-Val 2-Val 1. Additionally, the slight
downfield shift of the carbonyl group of Sta 1 compared to that of Sta 2 (175.3 vs 173.8) deter-
mined the presence of a free carboxylic acid in Sta 1. The full sequence of the molecule was
Microbial Natural Products as Antimalarials
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confirmed by key fragments observed in the MS/MS spectrum of the molecule where ions at
m/z 218, 317, 474 and 545 were indicative of the breakage of the Val 2-Val 1, Va1 1-Sta 2, Sta
2-Ala, and Ala-Sta1 amide bonds, respectively. 1H NMR and 13C NMR spectra for pepstatin K
are shown in S1 Appendix.
Fig 4. Compounds detected in the screen. Known (A) and unknown (B) compounds are indicated. The corresponding EC50 values, calculated using the
LDHmethod, are shown below each compound. Results of mean and standard deviation for the EC50 values are from three independent experiments in
triplicate.
doi:10.1371/journal.pone.0145812.g004
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Discussion
The screening described herein has proved to be a valuable and exploitable tool in the search
for new antimalarials. Due to the growing need for new drugs to treat this disease, exploring
new sources of chemical scaffolds could contribute to the identification of novel drugs with
new modes of action. Chemical libraries created by iterative synthesis around a few families of
compounds are not always the best option when the objective is to identify non-previously
exploited novel scaffolds. While several high throughput screens against P. falciparum of vast
compound collections have been previously published [18, 26], to date no high throughput
studies have been performed in the field of microbial natural products. One of the potential
challenges of using natural products collections is the expertise required to address the
Table 2. NMR data for pepstatin K (500 MHz, CD3OD, at 24°C).
Amino acid Position δC, mult δH, (mult, J in Hz) COSY HMBC
Sta 1 CO 175.3, C
α 39.9, CH2 2.44 (dd, 16.1, 4.4), 2.36 (m) β CO, Cβ, Cγ
β 70.9, CH 4.03 (m) α, γ CO, Cα
γ 52.5, CH 4.00 (m) β, δ
δ 41.4, CH2 1.57 (m), 1.35 (m) γ, ε Cγ, Cε, Cζ, Cζ’
ε 25.9, CH 1.63 (m) δ, ζ, ζ’ Cδ, Cζ, Cζ’
ζ 23.7, CH3 0.92 (m) ε Cε, Cζ
ζ’ 22.4, CH3 0.89 (m) ε Cε, Cζ’
Ala CO 175.4, C
α 50.9, CH 4.31 (q, 7.3) β CO, Cβ, CO-Sta 2
β 18.3, CH3 1.36 (d, 7.3) α CO, Cα
Sta 2 CO 173.8, C
α 41.4, CH2 2.36 (m), 2.31 (dd, 14.7, 5.9) β CO, Cβ, Cγ
β 71.1, CH 4.01 (m) α, γ CO, Cα
γ 52.8, CH 3.90 (m) β, δ
δ 41.2, CH2 1.57 (m), 1.35 (m) γ, ε Cγ, Cε, Cζ, Cζ’
ε 25.9, CH 1.63 (m) δ, ζ, ζ’ Cδ, Cζ, Cζ’
ζ 23.7, CH3 0.92 (m) ε Cε, Cζ
ζ’ 22.4, CH3 0.89 (m) ε Cε, Cζ’
Val 1 CO 173.8, C
α 61.0, CH 4.10 (d, 7.9) β CO, CO-Val 2, Cβ, Cγ, Cγ’
β 31.5, CH 2.05 (m) α, γ, γ’ CO, Cα, Cγ, Cγ’
γ 18.9, CH3 0.93 (m) β Cα, Cβ, Cγ’
γ’ 20.0, CH3 0.95 (m) β Cα, Cβ, Cγ
Val 2 CO 173.9, C
α 60.7, CH 4.18 (d, 7.9) β CO, CO-Ar, Cβ, Cγ, Cγ’
β 31.7, CH 2.05 (m) α, γ, γ’ CO, Cα, Cγ, Cγ’
γ 18.9, CH3 0.93 (m) β Cα, Cβ, Cγ’
γ’ 19.9, CH3 0.95 (m) β Cα, Cβ, Cγ
PE CO 174.2, C
CH2-Ar 43.6, CH2 3.59 (m) α CO, Ar-C, Cα
Ar-C 136.9, C
CH-α, α’ 130.2, CH 7.30 (m) CH2, γ CH2, Cγ
CH-β, β’ 129.6, CH 7.30 (m) γ Ar-C
CH-γ, γ’ 127.9, CH 7.23 (m) α, β Cβ
doi:10.1371/journal.pone.0145812.t002
Microbial Natural Products as Antimalarials
PLOS ONE | DOI:10.1371/journal.pone.0145812 January 6, 2016 12 / 16
complexity of isolating and elucidating the pure compound responsible for the activity from
positive extract identified in a primary screen. Unfortunately this process sometimes involves
the identification of previously described compounds as is the case of petasol [33] obtained in
the present study. The application of this sensitive technology [18] combined with the use of
semi-automated fractionation and miniaturized LC-MS, LC-HRMS and NMR analyses, has
allowed for a fast and efficient identification of minor extract components at an early stage of
the discovery process thus optimizing the identification of novel actives. Likewise, high
throughput technology has permitted the analysis of hundreds of extracts and multiple frac-
tions in a highly cost-effective and time-efficient manner. Another limitation for natural prod-
uct exploitation is in some cases the low yield of the active compounds that can be overcome
applying different scale-up strategies as well as traditional strain optimization of the produc-
tion of distinct metabolites or heterologous expression in suitable hosts.
While the identification of novel compounds is of major interest, known compounds should
not be disregarded since in many cases their antimalarial activity has not been previously
described and they could thus provide a starting point for the development of new antiplasmo-
dial agents. Drug repurposing constitutes a productive avenue for the identification of new
therapies. Examples are the use of antifungal imidazoles recently tested in clinical trials against
Chagas disease [34] or the recently approved combination therapy of nifurtimox (an anticha-
gasic agent) with eflornithine for the treatment of sleeping sickness [35].
In summary, the compounds identified in the present natural products screening provide
valuable information for antimalarial drug discovery from microbial sources. Although the
most druggable compounds identified exhibit EC50 values in the micromolar range, these hits
could be considered as good starting points for a lead optimization process. While the present
report describes the first data obtained in the screening of approximately one-seventh of the
Fig 5. Key HMBC correlations (H to C) and MS/MS fragments observed in the spectra of pepstatin K.
doi:10.1371/journal.pone.0145812.g005
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extracts available, efforts are currently underway to complete the analysis of the wealth of infor-
mation contained within the whole MEDINA natural product extract collection.
Supporting Information
S1 Appendix. 1H NMR and 13C NMR spectra for pepstatin K.
(PDF)
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(TIF)
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